Medication info
Combirucan Tablet 5/8 mg

Combirucan Tablet 5/8 mg

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tabletCandesartan Cilexetil›8mg / 1 tablet
Manufacturer / importer
Hanin Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablets
Packaging
30 tablets (10 tablets/PTP X 3)
Approval status
Active

MFDS item code 201702403 · Approved 2017.05.16 · Insurance code 657203090

Summary

Main use
Treatment of hypertension and heart failure, improvement of dyslipidemia, and suppression of the progression of atherosclerosis and cardiovascular risk
Who takes it
Adults · Children
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatment options should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: In patients at high risk of hypotension, such as those with volume depletion, administer an initial dose of 4 mg with careful monitoring. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including patients receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. There is limited experience with use in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min). 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience with use in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. The dose may be doubled at intervals of 2 weeks or longer, up to a maximum of 32 mg once daily, taking the patient's tolerability into account. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and should continue it throughout treatment. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted for maintenance therapy. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, based on the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.
Child dose
The safety and efficacy of this medicine have not been established in adolescents and children aged 18 years or younger. The safety and efficacy of this medicine have not been established in adolescents and children aged 18 years or younger.

Ingredients

Manufacturer
Hanin Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure, improvement of dyslipidemia, and suppression of the progression of atherosclerosis and cardiovascular risk

  • Essential hypertension
  • left ventricular systolic dysfunction
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol
  • smoking
  • family history of early coronary artery disease
View approved original text

This medication is prescribed for patients who require the simultaneous use of two drugs, Candesartan Cilexetil and Rosuvastatin. Candesartan Cilexetil helps control blood pressure and is used in patients with essential hypertension and heart failure with left ventricular systolic dysfunction. It is particularly effective when treatment with ACE inhibitors is insufficient or poorly tolerated. Rosuvastatin is mainly used for hypercholesterolemia and the prevention of atherosclerosis, helping patients with hyperlipidemia that is not controlled by diet. It also contributes to the reduction of the risk of stroke, myocardial infarction, and vascular reintervention in patients at high risk of cardiovascular disease. Therefore, this medication is used to simultaneously improve hypertension, hyperlipidemia, and the risk of cardiovascular disease.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatment options should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: In patients at high risk of hypotension, such as those with volume depletion, administer an initial dose of 4 mg with careful monitoring. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including patients receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. There is limited experience with use in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min). 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience with use in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. The dose may be doubled at intervals of 2 weeks or longer, up to a maximum of 32 mg once daily, taking the patient's tolerability into account. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and should continue it throughout treatment. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted for maintenance therapy. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, based on the LDL cholesterol level, treatment goal, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.

Child dose

The safety and efficacy of this medicine have not been established in adolescents and children aged 18 years or younger. The safety and efficacy of this medicine have not been established in adolescents and children aged 18 years or younger.

Precautions

This medication can cause serious harm to the fetus and newborn, especially during pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Patients with allergies to this drug, liver disease, severe liver dysfunction, renal failure, and myopathy should not take this medication. Women of childbearing potential should only take this medication if they fully understand the possibility of pregnancy and risks to the fetus, and should use appropriate contraceptive methods. Elderly patients or those with liver dysfunction, renal dysfunction, or hyperkalemia should use this medication carefully, and regular blood tests and liver function tests may be required during treatment. This medication may cause muscle-related side effects such as myalgia, myopathy, and rhabdomyolysis; if unexplained muscle pain or weakness occurs during treatment, consult a doctor immediately. This medication may affect liver function, so liver enzyme levels should be checked before and during treatment, and if liver dysfunction is severe, administration should be discontinued. Due to its blood pressure-lowering effects, hypotension or dizziness may occur, so caution is needed when driving or operating machinery. When used in combination with other antihypertensive medications or diuretics, potassium-sparing diuretics, etc., blood pressure, kidney function, and serum potassium levels should be monitored regularly. This medication may interact with certain drugs, so be sure to inform healthcare professionals about any other medications being taken. Pregnant or breastfeeding women should not take this medication, and breastfeeding should be discontinued if necessary. Safety in children has not been established, and use is not recommended. In case of overdose, appropriate treatment is required depending on the symptoms, and this medication is not removed by dialysis. When storing this medication, keep it out of the reach of children and store it in its original container.

Side effects

Headache, nasopharyngitis, localized infection, fatigue, generalized pruritus, dermatitis, itching, joint stiffness, limb pain, photophobia, dyspepsia, elevated blood sugar, decreased serum sodium, hand fractures, hypoglycemia, nephrolithiasis, cough, dizziness, positional vertigo, miliaria, periodontitis, chest discomfort, inflammation, foreign body sensation, nausea, elevated blood sugar, decreased serum sodium, hand fractures, hypoglycemia, nephrolithiasis, cough, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, constipation, abdominal pain, diarrhea, fever, relief, dyspnea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, memory decline, forgetfulness, amnesia, memory impairment, confusion, severe muscle weakness, ocular myasthenia, hypotension, hyperkalemia, renal function impairment, increased creatinine, elevated urea, increased potassium, decreased sodium, elevated ALT, elevated AST, elevated γ-GTP, liver dysfunction, jaundice, angioedema, increased blood pressure, cerebral infarction, spondyloarthritis myelopathy, musculoskeletal discomfort, pneumonia, femoral fracture, contusion, unstable angina, idiopathic pulmonary fibrosis, dizziness, positional dizziness, adrenal insufficiency, shock, syncope, loss of consciousness, paralysis, hypertonia, syncope, facial flushing, weight gain, facial edema, polydipsia, sleep disorders, decreased libido, forgetfulness, loss of appetite, increased appetite, tinnitus, taste disturbance, erectile dysfunction, joint pain, numbness, sensory abnormalities, chest discomfort, abdominal distention, syncope, generalized pain, muscle cramps, gout

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air or moisture from entering and kept at room temperature between 1°C and 30°C. This will help maintain the drug's effectiveness for a longer period.

Appearance and packaging

Appearance

Pink round film-coated tablets

Package unit

30 tablets (10 tablets/PTP X 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.